Top of Page
Skip main navigation

Luis Salgueiro, Ph.D.

Assistant Professor, College of Osteopathic Medicine 

Research Associate

Luis M Salgueiro, Ph.D., currently serves as Assistant Professor at the Institute for Neuro-Immune Medicine at Nova Southeastern University. Dr. Salgueiro is also a Biomedical Research Scientist affiliated to the Endocrine, Polypeptide and Cancer Institute at the Miami Veterans Affairs Healthcare System. Prior to joining INIM, he earned his professional degree and spent several years in the field of Veterinary Sciences (DVM). As veterinarian he acquired a considerable experience on the rational and humane use of domestic and laboratory animals for production and research purposes. He has and extended experience in the field of toxinology with an important training on antivenom and therapeutic antibodies production. He completed his early post-doctoral training on the screening and purification of biological active peptides from snake venom for its development as therapeutic agents for cancer. All these abilities are reinforced by his expertise in the design of biomedical studies to solve several medical conditions.

Over the last 10 years, he has been involved as Principal Investigator and Co-Investigator on several grants funded by the NIH, Department of Defense, Nova Southeastern University and the University of Miami. Dr. Salgueiro has laid a solid knowledge base on all the phases required for the evaluation of neuroactive biologicals and their development as CNS therapeutics.

Dr. Salgueiro has a well-suited preparation in endocrinology, neuropharmacology and peptide/protein interactions and is currently working and contributing with several research protocols for the study of alternative therapies for the treatment of aging and CNS neurologic conditions including cancer, diabetes, Post Traumatic Stress Disorder, Traumatic Brain Injury, Gulf War illness, and Alzheimer’s disease based on the evaluation of the beneficial effect of synthetic analogs of Growth Hormone-Releasing Hormone (GHRH) in the CNS.


Return to Our Team


  • Growth Hormone Releasing Hormone (GHRH) Antagonist: Evaluation of Beneficial Effects for Gulf War Illness   
  • To evaluate new therapeutic alternatives based on the beneficial effects of the highly biologically active analogs (antagonists) of Gonadotropin Releasing Hormone (GHRH) to alleviate Gulf War illness. 
  • Understanding Gulf War Illness (GWI): An Integrative Model Approach  
     To develop an experimental animal model of GWI to evaluate the use of selected anti-inflammatory drugs for the therapeutic approach of GWI and related neurological conditions. 
Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone-Releasing Hormone Peptide Analogues

Jeanne Dit Fouque K, Salgueiro LM, Cai R, Sha W, Schally AV, Fernandez-Lima F. ACS Omega. 2018 Jul 6;3(7):7432-7440. doi: 10.1021/acsomega.8b00375.


Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields

Stewart TS, Nagesetti A, Guduru R, Liang P, Stimphil E, Hadjikhani A, Salgueiro L, Horstmyer J, Cai R, Schally A, Khizroev S. Nanomedicine (Lond). 2018 Feb;13(4):423-438. doi: 10.2217/nnm-2017-0300.


Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells

Popovics P, Schally AV, Salgueiro L, Kovacs K, Rick FG. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1359-1364. doi: 10.1073/pnas.1620884114.


Part III: Experimental studies on antagonists of LH-RH and GH-RH in animal models of Alzheimer's disease: Projections for treatment of other neurological conditions

Schally, A & Salgueiro, L. (2015). Peptides. 72. 158-163.

Return to top of page